Financial results for the period ended Jun 30, 2026
As filed · Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
What happened
FactConcord Biotech Limited's Board of Directors approved the unaudited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2026, during a meeting held on July 31, 2026. The meeting commenced at 03:30 P.M. and concluded at 4:35 P.M. The filing is in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
ContradictedEBITDA for the financial year 2025 stood at INR 506 crores, which represents a growth of 17% on a year-on-year basis.
But in order to reach to the 40%, we need to have the injectable facility and Stellon business.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Backed by the world's largest portfolio of fermentation-based products, best-in-class regulatory compliance, n (management committed by FY27)
- We also expanded our customer base and product portfolio with the addition of new customers and products, stre (management committed by H1 FY27)
Evidence
- Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.(opens the original filing in a new tab)
- Earlier statement · FY25
- Latest statement · Q1 FY27
- Earlier statement · FY25
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%